Evaluating the Safety and Tolerability of OraVescent Fentanyl for Opioid Tolerant Patients With Noncancer Related Breakthrough Pain

• Status: Completed
• Trial end date: 2007-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety and tolerability of OraVescent fentanyl for the potential treatment of breakthrough pain episodes in patients who have chronic noncancer pain.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cephalon
• Treatments: Fentanyl

Criteria

Inclusion Criteria:

• Chronic pain diagnosis

• Opioid tolerant

• Has on average 1-4 breakthrough pain episodes per day

Exclusion Criteria:

• Drug abuse history

• Cardiopulmonary disease

• Monoamine oxidase inhibitors (MAOIs)

• Expected to have surgery to relieve the pain